LiDCO Group Plc Hemodynamic management in COVID-19 patients (8811L)

TIDMLID

RNS Number : 8811L

LiDCO Group Plc

05 May 2020

This announcement contains inside information

for the purposes of Article 7 of Regulation (EU) No 596/2014 (MAR)

LiDCO Group Plc

("LiDCO" or the "Company")

Hemodynamic management in COVID-19 patients and Q1 sales update

LiDCO (AIM: LID), a leading supplier of hemodynamic monitoring solutions, welcomes the recent educational webinar from the European Society of Intensive Care Medicine ('ESICEM') regarding hemodynamic management in COVID-19 patients. The panel consisted of four international experts who discussed current World Health Organisation COVID-19 treatment guidelines and explored the patient benefits of using advanced hemodynamic monitoring in such treatment.

During the discussions, Senior Consultant Antonio Messina at Humanitas Hospital, Italy discussed the frontline strategies for treating COVID-19 patients and the importance of managing these ventilated patients' physiology with functional hemodynamic tests. During Dr Messina's speech he called out the importance of using a combination of a ventilator and a hemodynamic monitor to perform an end expiratory occlusion test ('EEOT') to assess the patient's fluid status.

This point was reinforced by Professor Jacques Duranteau, Head of Anaesthesia and Critical Care at Bicetre hospital, Paris, who referenced the need to employ a conservative fluid strategy and discussed the use of another ventilator-associated method, the tidal volume challenge ('TVC'), as a means to assess a patient's fluid status to prevent giving COVID-19 patients any excess fluid.

To perform these tests requires a precise measurement of the patient's advanced hemodynamic parameters. The LiDCO monitor is able to meet this need to measure these small changes over a short period of time and is the only monitor on the market to have both the EEOT and TVC as in-built guided clinical protocols.

As previously announced in LiDCO's Full-Year Results release in April 2020, the Company has seen a strong lift in demand for its hemodynamic monitoring systems due to COVID-19. Over 200 monitors have been sold, predominately in the UK, in the first three months of the financial year compared with 219 sold in the whole of previous financial year. LiDCO has been able to supply the monitors to ICU units around the world where patients with the most acute symptoms of COVID-19 are being treated.

LiDCO sales in Q1 of this year (three months ended 30 April 2020) were GBP4.4m up 179% on the corresponding period last year. As expected, Q1 sales have therefore already significantly exceeded the total sales of GBP3.5m the Company achieved in H1 last year (6 months to 31 July 2019).

To listen to the ESICEM webinar click here: https://bit.ly/2VDerOI

To find out more information about EEOT and TVC click here: http://www.lidco.com/what-are-preload-responsive-ventilator-tests/

Matt Sassone, CEO of LiDCO, said: "This ESICEM webinar has highlighted two key measurements to assist in the treatment of COVID-19 patients, the end expiratory occlusion test (EEOT) and tidal volume challenge (TVC), which LiDCO's technology already has in-built. This demonstrates once again the core benefits of our technology in the critical care environment and our technology leadership in the advanced hemodynamic monitoring market. I am proud of how our team met the challenge of a substantial surge in orders in Q1, thereby doing our part to help hospitals and patients affected by Covid-19."

For further information, please contact:

 
LiDCO Group Plc                    www.lidco.com 
Matt Sassone (CEO)                 Tel: [phone] 
Tim Hall (CFO) 
 
N+1 Singer                         Tel: [phone] 
Aubrey Powell, George Tzimas (Corporate 
 Finance) 
Tom Salvesen (Corporate Broking) 
 
Walbrook PR Ltd                    Tel: [phone] or [e-mail] 
Paul McManus                       Mob: [phone] 
Lianne Cawthorne                   Mob: [phone] 
 
 

About LiDCO Group Plc ( www.lidco.com )

LiDCO is a supplier of non-invasive and minimally invasive hemodynamic equipment to hospitals used to monitor the amount of blood flowing around the body and ensure that vital organs are adequately oxygenated. LiDCO's products facilitate the application of hemodynamic optimisation protocols for high risk patients in both critical care units and in the operating theatre.

Increasingly clinical studies have shown that the optimisation of patients' hemodynamic status in high risk patients produces better outcomes and reduced hospital stay. LiDCO's computer-based technology, developed originally at St Thomas' Hospital in London, has been shown to significantly reduce morbidity and complications, length of stay and overall costs associated with major surgery.

In critical care, LiDCO's products have various in-built guided clinical protocols such as an end expiratory occlusion test (EEOT) and a tidal volume challenge (TVC), as a means to assess a patient's fluid status. These methods have been referenced by key opinion leaders as an important part of the treatment pathway for ventilated patients with the Covid-19 coronavirus in critical care.

Key Products:

LiDCOunity: a hemodynamic monitor that combines the full suite of LiDCO technology (non-invasive, minimally invasive and calibrated technologies) into one platform. Designed to have the flexibility to adapt to a patient's changing acuity, the product enables clinicians to seamlessly transition between non-invasive, minimally invasive and calibrated hemodynamic monitoring.

LiDCOplus : a computer-based platform monitor used in the Intensive Care Unit for real-time continuous display of hemodynamic parameters including cardiac output, oxygen delivery and fluid-volume responsiveness (PPV% and SVV%).

LiDCOrapid : a cardiac output monitor designed specifically for use in the operating theatre for fluid and drug management. The monitor enables anaesthetists to receive accurate and immediate feedback on the patient's fluid and hemodynamic status - a key measure of overall well-being before, during and after surgery. The LiDCOrapid provides:

-- early and rapid warning of hemodynamic change to aid choice of therapeutic route: fluid or drug

-- quantification of hemodynamic response guidance on effective delivery of fluids to ensure the right amount at the right time

The software incorporated into LiDCOrapid allows the LiDCOrapid monitor to co-display Medtronic's level of consciousness parameter ('BIS(TM') )* and add the convenience of CNSystem's continuous non-invasive blood pressure monitoring ('CNAP')**. This addresses a growing requirement for non-invasive monitoring solutions that are more comprehensive and can effectively replace multiple single parameter monitors.

LiDCOview : an easy-to-use graphical display of historical LiDCOplus and LiDCOrapid hemodynamic data.

*BIS (TM) and Bispectral Index are trademarks of Medtronic registered in the US and foreign countries.

**CNAP(TM) is a trademark of CNSystems Medizintechnik AG.

LiDCO monitors use single-patient disposables (sensors or smartcards) which provide an ongoing revenue stream.

LiDCO Distribution Network :

LiDCO sells directly to hospitals in the UK and USA and through a network of specialty critical care and anaesthesia distributors in the rest of the world.

LiDCO's headquarters are in London and its shares are traded on AIM.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

UPDEAXSLEEDEEFA

(END) Dow Jones Newswires

May 05, 2020 05:21 ET (09:21 GMT)